ATE315393T1 - Verwendung von histamin um die blutkonzentration des histamins zu erhöhen - Google Patents

Verwendung von histamin um die blutkonzentration des histamins zu erhöhen

Info

Publication number
ATE315393T1
ATE315393T1 AT98957777T AT98957777T ATE315393T1 AT E315393 T1 ATE315393 T1 AT E315393T1 AT 98957777 T AT98957777 T AT 98957777T AT 98957777 T AT98957777 T AT 98957777T AT E315393 T1 ATE315393 T1 AT E315393T1
Authority
AT
Austria
Prior art keywords
histamine
methods
levels
natural killer
killer cell
Prior art date
Application number
AT98957777T
Other languages
English (en)
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Kurt R Gehlsen
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Application granted granted Critical
Publication of ATE315393T1 publication Critical patent/ATE315393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ladders (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Road Signs Or Road Markings (AREA)
  • Saccharide Compounds (AREA)
AT98957777T 1997-11-13 1998-11-10 Verwendung von histamin um die blutkonzentration des histamins zu erhöhen ATE315393T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/969,384 US6071942A (en) 1996-05-14 1997-11-13 Elevation of circulating blood histamine levels

Publications (1)

Publication Number Publication Date
ATE315393T1 true ATE315393T1 (de) 2006-02-15

Family

ID=25515502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957777T ATE315393T1 (de) 1997-11-13 1998-11-10 Verwendung von histamin um die blutkonzentration des histamins zu erhöhen

Country Status (15)

Country Link
US (2) US6071942A (de)
EP (1) EP1047422B1 (de)
JP (1) JP2001522885A (de)
KR (1) KR20010031979A (de)
CN (1) CN1128618C (de)
AT (1) ATE315393T1 (de)
AU (1) AU760068B2 (de)
CA (1) CA2310255A1 (de)
DE (1) DE69833225T2 (de)
DK (1) DK1047422T3 (de)
ES (1) ES2256971T3 (de)
HK (1) HK1035330A1 (de)
IL (1) IL135872A0 (de)
PT (1) PT1047422E (de)
WO (1) WO1999025341A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
ES2225156T3 (es) * 1999-06-03 2005-03-16 Maxim Pharmaceuticals, Inc. Composiciones oftalmicas que contienen histamina y usos de las mismas.
KR20040058192A (ko) * 2001-10-19 2004-07-03 맥심 파마수티컬즈 인크. 간 질환 치료용으로서의 히스타민 용도
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
ZA200701781B (en) * 2004-09-03 2008-11-26 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
CA2893438A1 (en) * 2012-12-05 2014-06-12 Biohealthonomics Inc. Methods for restoration of histamine balance
US9023881B2 (en) 2012-12-05 2015-05-05 Biohealthonomics Inc. Methods for restoration of histamine balance
US10117908B2 (en) 2013-10-17 2018-11-06 Grant Labs, Inc. Suppression of cellular transformation and dysplasia by topical application of lefty

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1911429A1 (de) * 1969-03-06 1970-09-24 Waldhof Zellstoff Fab Lipophile Puryl-(6)-histaminderivate und Verfahren zu ihrer Herstellung
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells
ATE136786T1 (de) * 1989-09-19 1996-05-15 Syntello Inc Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor- agonisten
US5135491A (en) * 1990-11-02 1992-08-04 Baldwin Brian E Patient controlled infusion apparatus and method
EP0642333B1 (de) * 1992-04-22 1998-06-24 Molecular Rx., Inc. Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
SE513429C2 (sv) * 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
JPH07165582A (ja) * 1993-12-08 1995-06-27 Seiji Takayama 免疫抗癌剤の抗癌効果増強剤
US5478211A (en) * 1994-03-09 1995-12-26 Baxter International Inc. Ambulatory infusion pump
CA2196756A1 (en) * 1994-08-08 1996-02-22 Jan Urban Kristoffer Hellstrand Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels

Also Published As

Publication number Publication date
AU760068B2 (en) 2003-05-08
KR20010031979A (ko) 2001-04-16
IL135872A0 (en) 2001-05-20
EP1047422B1 (de) 2006-01-11
WO1999025341A1 (en) 1999-05-27
EP1047422A1 (de) 2000-11-02
PT1047422E (pt) 2006-05-31
US6071942A (en) 2000-06-06
ES2256971T3 (es) 2006-07-16
DE69833225T2 (de) 2006-08-10
DK1047422T3 (da) 2006-04-18
AU1395599A (en) 1999-06-07
JP2001522885A (ja) 2001-11-20
HK1035330A1 (en) 2001-11-23
CA2310255A1 (en) 1999-05-27
CN1285744A (zh) 2001-02-28
CN1128618C (zh) 2003-11-26
DE69833225D1 (de) 2006-04-06
US6613788B1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
DE69030880T2 (de) Zusammensetzung zur Stimulierung des Immunsystems
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
KR910016317A (ko) 이온전기도입에 의한 딜리버리를 증가시키는 방법 및 여기에 사용되는 조성물
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
MX9601150A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida.
DE69325998T2 (de) Verwendung von beta-hydroxy-beta-methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
ATE419875T1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
IL105339A0 (en) Pharmaceutical compositions containing undenatured whey protein concentrate
George Adverse effects with PUVA and UVB phototherapy
BRPI0317064B8 (pt) composições compreendendo células dendríticas parcialmente amadurecidas in vitro
DE69833225D1 (de) Verwendung von histamin um die blutkonzentration des histamins zu erhöhen
WO1997042968A3 (en) Administration of histamine for therapeutic purposes
BR9707154A (pt) Modulaç o da express o de citocina em th1/th2 por ribavirina e análogos de ribavirina em linfócitos t ativados
TR200200620T2 (tr) Levosimendan farmasötik solüsyonları
DK1014990T3 (da) Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
TR200003101T2 (tr) Levosimendan ve aljinik asit içeren kararlı kompozisyonlar
UA85548C2 (ru) Применение водного экстракта листьев красного винограда для предупреждения перехода от клинически незначительных ранних стадий хронической венозной недостаточности к i, ii или iii стадии
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1047422

Country of ref document: EP

REN Ceased due to non-payment of the annual fee